Press Releases

January 19, 2023 Oakville, Ontario – January 19, 2023: NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMDBF) (FRA:6UF0) (“NeonMind” or the “Company”) announces that, in preparation for a reverse merger transaction with Lancaster Lithium Inc. (“Lancaster Lithium”) as previously announced

Read More »

January 11, 2023 Oakville, Ontario – January 11, 2023: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) announces that, in preparation for the reverse merger transaction with Lancaster Lithium Inc. previously announced on December 14, 2022, NeonMind has

Read More »

December 14, 2022 Oakville, Ontario – December 14, 2022: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) is pleased to announce that it has signed a binding letter agreement dated December 14, 2022 with Lancaster Lithium Inc. (“Lancaster

Read More »

December 9, 2022 Oakville, Ontario – December 9, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink:NMDBF) (FSE:6UF) (“NeonMind” or the “Company”) announced today that Rob Tessarolo, a director on the NeonMind Board of Directors, was appointed Chief Executive Officer and

Read More »

November 8, 2022 3:45PM EDT Oakville, Ontario – November 8, 2022: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) announced the strategic decision to seek to divest its lead drug development program NEO-001 and undertake a search for

Read More »

May 30, 2022 6:00pm EDT Oakville, Ontario – May 30, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF0) (“NeonMind” or the “Company”) announced today that has made changes to its Management, Board of Directors and Advisory Board to support

Read More »

April 21, 2021 8:00am EDT Engages Thrive Health, a Leading Digital Patient Care Platform to Streamline Care Programs and Data Collection OAKVILLE, ON / ACCESSWIRE / April 21, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBD)(FRA:6UF) (“NeonMind” or the “Company“), announced today it

Read More »

April 11, 2021 8:00am EDT Initiates Medical Adoption Program with Impetus Digital, a Leading Healthcare Platform for Virtual Medical Education OAKVILLE, ON / ACCESSWIRE / April 19, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBD)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug development

Read More »

April 11, 2021 8:00am EDT Partnered with SRx Health Solutions and BioScript Solutions to Build Out a Network of NeonMind-branded Specialty Mental Health Clinics Across Canada Oakville, Ontario – April 12, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA:

Read More »

April 11, 2021 8:00am EDT Oakville, Ontario – April 11, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”) an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from

Read More »

April 08, 2021 8:00am EDT Oakville, Ont. – April 8, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”) an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from

Read More »

March 23, 2021 8:00am EDT To Deliver Low Dose Intravenous Ketamine for Mood and Anxiety Disorders, a Recommended Treatment by Canadian Guidelines, Upon Clinic Licensing OAKVILLE, ON / ACCESSWIRE / March 23, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (“NeonMind” or the

Read More »